Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §103 only | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.0% | +43.8% |
| XIAO, YAN | 1 | 67.9% | +51.5% |
| OGLES, MATTHEW ERIC | 1 | 51.5% | +55.0% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 60.9% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 21d |
| 18102263 | EYE-TRACKING DEVICE AND METHOD FOR TESTING VISUAL PROCESSING CAPABILITIES | OGLES, MATTHEW ERIC | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16973573 | A METHOD OF PRECISION CANCER THERAPY | SULLIVAN, STEPHANIE LAUREN | 45d overdue |
| 18122839 | COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE | XIAO, YAN | 15d |
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 21d |
| 18102263 | EYE-TRACKING DEVICE AND METHOD FOR TESTING VISUAL PROCESSING CAPABILITIES | OGLES, MATTHEW ERIC | 34d |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1642 | 1 |
| 3791 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324563 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | BAUSCH, SARAE L | 1699 | §103 | Non-Final OA | 21d | Pending | May 26, 2023 |
| 18122839 | COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE | XIAO, YAN | 1642 | §103 | Non-Final OA | 15d | Pending | Mar 17, 2023 |
| 18102263 | EYE-TRACKING DEVICE AND METHOD FOR TESTING VISUAL PROCESSING CAPABILITIES | OGLES, MATTHEW ERIC | 3791 | §101 | Final Rejection | 34d | Pending | Jan 27, 2023 |
| 16973573 | A METHOD OF PRECISION CANCER THERAPY | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Final Rejection | 45d overdue | Pending | Dec 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial